Anaplastic Large Cell Lymphoma Latest Advances

Find the Latest Research About Anaplastic Large Cell Lymphoma

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 3652 publications

Rapidly progressive papulonodular eruption in a febrile patient.

Rapidly progressive papulonodular eruption in a febrile patient.

Journal: JAAD case reports

Published: March 30, 2026

Jaye DL, Feldman AL. ALK-negative anaplastic large cell lymphoma with JAK2 rearrangement mimicking classic Hodgkin lymphoma. Blood. 2023;141(17):2160.

Jaye DL, Feldman AL. ALK-negative anaplastic large cell lymphoma with JAK2 rearrangement mimicking classic Hodgkin lymphoma. Blood. 2023;141(17):2160.

Journal: Blood

Published: March 26, 2026

Diagnostic and treatment challenges associated with the atypical presentation of ALK-positive anaplastic large cell lymphoma in a Jehovah's Witness patient.

Diagnostic and treatment challenges associated with the atypical presentation of ALK-positive anaplastic large cell lymphoma in a Jehovah's Witness patient.

Journal: BMJ case reports

Published: March 23, 2026

Research Progress in ALK+/- Anaplastic Large Cell Lymphoma--Review

Research Progress in ALK+/- Anaplastic Large Cell Lymphoma--Review

Journal: Zhongguo shi yan xue ye xue za zhi

Published: March 18, 2026

Breast-implant associated unicentric castleman disease: a case report.

Breast-implant associated unicentric castleman disease: a case report.

Journal: Current problems in cancer. Case reports

Published: March 16, 2026

Development of Primary Cutaneous Anaplastic Large Cell Lymphoma Following Treatment With Upadacitinib for Atopic Dermatitis.

Development of Primary Cutaneous Anaplastic Large Cell Lymphoma Following Treatment With Upadacitinib for Atopic Dermatitis.

Journal: Cutis

Published: March 16, 2026

Enhanced Efficacy and Safety of 177Lu-Anti-CD25 Radioimmunotherapy by Combination with Targeted Anticancer Agents.

Enhanced Efficacy and Safety of 177Lu-Anti-CD25 Radioimmunotherapy by Combination with Targeted Anticancer Agents.

Journal: Molecular pharmaceutics

Published: March 03, 2026

Development of a Taste-Masked, Dose-Flexible, Multiparticulate Pediatric Dosage Form: Case Study of Crizotinib, a Challenging Pediatric Formulation.

Development of a Taste-Masked, Dose-Flexible, Multiparticulate Pediatric Dosage Form: Case Study of Crizotinib, a Challenging Pediatric Formulation.

Journal: Pharmaceutical medicine

Published: March 02, 2026

Reply: Estimating the Prevalence of Breast Implant-Associated Anaplastic Large-Cell Lymphoma: A Systematic Review.

Reply: Estimating the Prevalence of Breast Implant-Associated Anaplastic Large-Cell Lymphoma: A Systematic Review.

Journal: Plastic and reconstructive surgery

Published: February 25, 2026

Beyond the Surface: Deciphering the Role of Genetic Susceptibility in BIA-ALCL Pathogenesis.

Beyond the Surface: Deciphering the Role of Genetic Susceptibility in BIA-ALCL Pathogenesis.

Journal: Biomedicines

Published: February 10, 2026

Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integration.

Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integration.

Journal: British journal of haematology

Published: February 06, 2026

[Erratum to "Breast implants and cancer: Anaplastic large cell lymphoma associated with breast implants" [Annales de Chirurgie Plastique Esthétique, 70/6 (November 2025), pp. 572-80]].

[Erratum to "Breast implants and cancer: Anaplastic large cell lymphoma associated with breast implants" [Annales de Chirurgie Plastique Esthétique, 70/6 (November 2025), pp. 572-80]].

Journal: Annales de chirurgie plastique et esthetique

Published: January 31, 2026

Showing 1-12 of 3,652

Last Updated: 04/28/2026